摘要
为探究罗沙司他联合重组人促红素,在尿毒症肾性贫血维持性血液透析患者治疗中的应用效果。选取2020年2月—2022年12月期间贵州医科大学附属肿瘤医院收治的60例尿毒症肾性贫血患者作为研究对象,按顺序编码将其分为对照组和实验组,对照组纳入的30例人员(重组人促红素治疗),实验组纳入的30例人员(罗沙司他+重组人促红素治疗)。统计对比纳入患者的血液营养指标、肾功能水平、炎性因子水平、铁代谢指标与不良反应发生率。结果显示,罗沙司他联合重组人促红素治疗方法运用后,实验组对比对照组,患者部分研究数据有明确优化意义(P<0.05)。临床疗效积极,可全面改善患者肾脏功能,优化炎症因子水平,安全可靠,推广应用价值较高。
To explore the therapeutic effect of rosalista combined with recombinant human erythropoietin in maintenance hemodialysis patients with Uremia and renal anemia.From February 2020 to December 2022,60 patients with Uremia and renal anemia who were admitted to The Affiliated Cancer Hospital of Guizhou Medical University were selected as the research objects,and were divided into the control group and the experimental group according to the sequence code.The 30 persons included in the control group(treated with recombinant human erythropoietin)and the 30 persons included in the experimental group(treated with rosastal+recombinant human erythropoietin).Statistical comparison of included patients:blood nutritional indicators;Renal function level;Inflammatory factor levels;Iron metabolism indicators;The incidence of adverse reactions.The results showed that after the combination of rosacetam and recombinant human erythropoietin treatment method was applied,the experimental group compared to the control group showed clear optimization significance in some patient study data(P<0.05).The study found that rosastat combined with recombinant human erythropoietin has a positive clinical effect in the treatment of maintenance hemodialysis patients with Uremia and renal anemia,which can comprehensively improve the renal function of patients,optimize the level of inflammatory factors,safe and reliable,and has a high value of promotion and application.
作者
司马重阳
SIMA Chongyang(The Affiliated Cancer Hospital of Guizhou Medical University,Guiyang,Guizhou 550001)
出处
《科技与健康》
2023年第6期56-58,共3页
Technology and Health
作者简介
司马重阳(1988-),男,贵州医科大学附属肿瘤医院主治医师,研究方向为肾内科(血液透析及血管通路)。
